NeuroMetrix to Partner with Omron Healthcare for Distribution of NC-stat DPNCheck in Japan

  NeuroMetrix to Partner with Omron Healthcare for Distribution of NC-stat
  DPNCheck in Japan

Business Wire

WALTHAM, Mass. -- April 24, 2013

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the
treatment of diabetic peripheral neuropathy (DPN), announced that it had
entered into an agreement with Omron Healthcare Co., Ltd. to be the exclusive
distributor for NC-stat^® DPNCheck^® in Japan. NC-stat DPNCheck is a rapid,
accurate and quantitative point-of-care test to detect diabetic peripheral
neuropathy at an early stage allowing physicians to select appropriate
treatment. DPN is the most common complication of diabetes, affecting over
half of people with diabetes. DPN causes significant morbidity including pain,
increased risk of falling in the elderly, and is the primary trigger for
diabetic foot ulcers, which may require lower extremity amputations.

According to 2012 International Diabetes Federation (IDF) estimates, diabetes
affects over seven million people in Japan, making Japan one of the top ten
countries globally in terms of prevalence of the disease, and second among
developed nations after the United States. Treatment outcomes for diabetes and
its complications continue to be a primary focus of both the Ministry of
Health, Labor and Welfare (MHLW) as well as the medical community within
Japan. A global leader in research and clinical practice in both diabetes and
DPN, Japan continues to seek improved outcomes for patients. Japan is also the
only market globally where Kinedak (epalrestat), a pharmaceutical specifically
for the treatment of DPN, is available.

Omron Healthcare is a leading manufacturer and distributor of wellness
products. Omron’s market-leading products include home blood pressure
monitors, fitness tools, such as pedometers and heart rate monitors, and
electrotherapy devices. It provides devices and services focused on lifestyle
diseases such as hypertension, diabetes and other chronic diseases. Omron
Healthcare has an installed base of over 10,000 vascular screening devices
(VP-1000 plus) in Japan. The VP-1000 plus measures the blood flow in the
peripheral arteries, which is often a concern among patients with DPN. Omron’s
products are synergistic with NC-stat DPNCheck. Its distribution channel
includes a strong direct sales force and local distributor network. Omron
Healthcare is well positioned to launch the NC-stat DPNCheck in Japan and
provide medical professionals focused on diabetes the tools they need to
screen and diagnose DPN.

“We are pleased to be able to provide our customers with an innovative and
proven technology in the NC-stat DPNCheck” said Isao Ogino, Director and
Senior Managing Officer of Omron Healthcare. “There is a strong synergy
between the VP-1000 plus and NC-stat DPNCheck from both a clinical and
operational viewpoint. Our partnership with NeuroMetrix allows us to once
again provide access to innovative and proven medical care that is meaningful
to patients.”

"Omron’s long history of innovation and results in Japan make them the obvious
choice for a partner as we seek to enter this important market” said Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “The
presence of locally available pharmaceutical treatments for DPN which
compliment the diagnostic capability of NC-stat DPNCheck make Japan a unique
market opportunity for us and Omron.”

Orient Strategy K.K., a consulting firm based in Japan, facilitated this
partnership between NeuroMetrix and Omron Healthcare.

About Omron Healthcare Co., Ltd.

Omron Healthcare, headquartered in Kyoto, is a global leader in health care
monitoring. The company offers a wide range of devices and services that help
prevent and manage lifestyle diseases such as blood pressure monitors, body
composition monitors and activity counters as well as medical devices such as
vascular screening devices and visceral fat monitors in more than 100
countries. For more information on Omron Healthcare, visit

About NeuroMetrix

NeuroMetrixis a medical device company that develops and markets home use and
point-of-care devices for the treatment of diabetic neuropathies, which affect
over 50% of people with diabetes. If left untreated, diabetic neuropathies
trigger foot ulcers that may require amputation and cause disabling chronic
pain. The annual cost of diabetic neuropathies has been estimated at$14
billioninthe United States. The company markets the SENSUS™ Pain Management
System for treating chronic pain, focusing on physicians managing patients
with painful diabetic neuropathy and similar peripheral neuropathies. The
company also markets the NC-stat^®DPNCheck^®device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visit


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.